Seeking Alpha
 

Zimmer Biomet Holdings, Inc. (ZBH)

- NYSE
  • Dec. 4, 2014, 10:37 AM
    • In an effort to facilitate its approval of its planned acquisition of Biomet, Zimmer Holdings (ZMH -0.1%) proposes a remedy package to the European Commission (EC). It includes the divestiture of one unicompartmental knee brand and one elbow brand in the European Economic Area (EEA) and one total knee brand in two EEA countries.
    • The EC will market test the remedy package in the coming days. Meanwhile, it has "stopped the clock" on its review of the merger. Zimmer expects the transaction to close in Q1 2015.
    • Previously: EC extends review period for Zimmer/Biomet deal (Nov. 18, 2014)
    • Previously: Zimmer to acquire Biomet for $13.35B (April 24, 2014)
    | Comment!
  • Nov. 18, 2014, 12:22 PM
    | Comment!
  • Oct. 23, 2014, 8:05 AM
    • Zimmer Holdings (NYSE:ZMH) Q3 results ($M): Revenues: 1,106.0 (+3.0%); Gross Profit: 807.7 (+8.3%); R&D Expense: 46.1 (-6.7%); SG&A Expense: 443.5 (+9.9%); Operating Income: 251.2 (+18.7%); Net Income: 165.5 (+7.2%); EPS: 0.96 (+6.7%); Quick Assets: 1,747.1 (-3.3%); CF Ops: 255.7.
    • Revenue By Geographic Segment: Americas: 637.9 (+0.8%); Europe: 270.7 (+6.2%); Asia Pacific: 197.4 (+5.9%).
    • Revenue By Product Category: Reconstructive: 823.8 (+4.5%), Knees: 461.4 (+6.2%), Hips: 315.6 (+2.4%); Extremities: 46.8 (+2.9%); Dental: 53.9 (-2.2%); Trauma: 77.8 (-0.9%); Spine: 51.0 (+6.3%); Surgical & Other: 99.5 (-4.7%).
    • 2014 Guidance: Revenue growth: ~2.25% from 2.0 - 3.0%; EPS: ~$4.65 from $4.65 - 4.75; non-GAAP EPS: ~$6.05 from $6.00 - 6.10.
    | Comment!
  • Oct. 23, 2014, 7:33 AM
    • Zimmer Holdings (NYSE:ZMH): Q3 EPS of $1.35 beats by $0.05.
    • Revenue of $1.11B (+3.7% Y/Y) beats by $10M.
    • Press Release
    | Comment!
  • Oct. 19, 2014, 6:37 PM
    • Zimmer Holdings (NYSE:ZMH) will report Q3 results on October 23 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is EPS of $1.30 on revenues of $1.1B.
    | Comment!
  • Oct. 7, 2014, 11:57 AM
    • BC, Canada-based Xenon Pharmaceuticals (XENE) is set for its IPO of 4M shares at $10 -12.
    • The clinical-stage biopharmaceutical firm discovers and develops differentiated therapeutics for orphan indications based on its Extreme Genetics platform. It focuses its discovery efforts on rare human diseases with extreme traits, including diseases caused by mutations in ion channels.
    • The Extreme Genetics platform yielded the first gene therapy product approved in the EU, uniQure's (QURE +1.5%Glybera (alipogene tiparvovec) for the treatment of adult patients with familial lipoprotein lipase deficiency.
    • Its pharma partners include (TEVA -0.3%), Genentech (OTCQX:RHHBY -2.5%) and Merck (MRK -1.2%). Collaborations have generated over $140M in revenue to Xenon so far. Future milestone payments could potentially surpass $1B.
    • The company's lead product is TV-45070 for the treatment of osteoarthritis of the knee. A 300-patient Phase 2b clinical trail run by Teva subsidiary Ivax International GmbH is underway.
    • A second product candidate, GDC-0276, for the treatment of pain is being developed in collaboration with Genentech. A Phase 1 study commenced in September 2014.
    • S-1
    • Osteoarthritis of the knee-related tickers: (AMPE +0.3%)(FLXN -4.6%)(ANIK -1.2%)(ZMH -0.7%)
    | 2 Comments
  • Sep. 1, 2014, 10:59 AM
    • Zimmer Holdings (NYSE:ZMH) will hear back from EU antitrust authorities by Oct. 3 over whether or how it will be allowed to pursue its $13.4B takeover of rival Biomet (Pending:BMET).
    • Zimmer originally sought approval in June, but the EU regulator paused the review because the company's submission was lacking details.
    | Comment!
  • Aug. 26, 2014, 7:16 AM
    • Zimmer Holdings (NYSE:ZMH) declares $0.22/share quarterly dividend, in line with previous.
    • Forward yield 0.88%
    • Payable Oct. 31; for shareholders of record Sept. 26; ex-div Sept. 24.
    | Comment!
  • Jul. 24, 2014, 1:04 PM
    • Zimmer Holdings (ZMH -3.5%) Q2 results: Net Sales: $1,182.9M (+1.1%), Reconstructive: $890.4M (+2.6%), Dental: $61.1M (-0.5%), Trauma: $78.8M (+6.3%), Spine: $52.2M (-3.7%), Surgical & Other: $100.4M (-10.2%); COGS: $333.2 (+3.0%); Gross Profit: $849.7M (+0.4%); R&D Expense: $48.1M (-12.4%); SG&A Expense: $455.8M (0.5%); Operating Income: $259.3M (+23.2%); Net Income: $176.1M (+16.1%); EPS: $1.03 (+15.7%); Quick Assets: $1,698.0M (-6.1%); CF Ops (1H): $442.9M (+19.6%).
    • 2014 Guidance: revenue growth: 2.0 - 3.0% from 3.0 - 5.0%; diluted GAAP EPS: $4.65 - 4.75 from $4.90 - 5.10; diluted non-GAAP EPS: $6.00 - 6.10 from $6.00 - 6.20.
    | Comment!
  • Jul. 24, 2014, 7:37 AM
    • Zimmer Holdings (NYSE:ZMH): Q2 EPS of $1.49 beats by $0.01.
    • Revenue of $1.18B (+0.9% Y/Y) misses by $30M.
    • Press Release
    | Comment!
  • May 23, 2014, 7:04 AM
    • Zimmer Holdings, Inc. (ZMH) declares $0.22/share quarterly dividend, in line with previous.
    • Forward yield 0.86%
    • Payable July 25; for shareholders of record June 27; ex-div June 25.
    | Comment!
  • Apr. 24, 2014, 12:46 PM
    | Comment!
  • Apr. 24, 2014, 9:28 AM
    | 1 Comment
  • Apr. 24, 2014, 7:43 AM
    • Zimmer (ZMH) says the transaction will "position the combined company as a leader in the $45B musculoskeletal industry," adding that "the complementary nature of the two businesses adds diversity and scale across various geographies and product categories."
    • Zimmer expects the purchase to be "double-digit accretive" to its EPS in the first year after closing, and to boot its cash flow from operations by 1.5 times. The company also forecasts annual synergies of $135M in the first year and $270M by the third year.
    • The combined 2013 revenues of the companies were $7.8B and adjusted EBITDA was $2.8B.
    • Zimmer will pay $10.35B in cash and the rest in shares. The company will help fund the deal with a $3B senior unsecured term loan and newly issued senior notes.
    • Zimmer shares continue to climb and are +11.5%. (PR)
    • Previous
    • Zimmer Q1 earnings
    | Comment!
  • Apr. 24, 2014, 7:21 AM
    • Zimmer (ZMH) has agreed to Biomet for $13.35B in cash and stock, with the deal including debt.
    • Zimmer shares are +6.3%. (PR)
    | Comment!
  • Apr. 24, 2014, 7:20 AM
    • Zimmer Holdings (ZMH): Q1 EPS of $1.50 beats by $0.03.
    • Revenue of $1.16B (+1.8% Y/Y) misses by $20M.
    • Press Release
    | Comment!
Visit Seeking Alpha's
ZBH vs. ETF Alternatives
Company Description
Zimmer Biomet Holdings Incis engaged in designing, manufacturing & marketing orthopaedic reconstructive products; sports medicine, biologics, extremities & trauma products; spine, bone healing, craniomaxillofacial & thoracic products &dental implants.